steady-state in patients [Design Issues]

posted by qualityassurance – 2025-01-09 11:59 (6 d 01:23 ago) – Posting: # 24334
Views: 125

Hi Helmut,

Recently a paper1 is published which shows Novonordisk conducted steady state study to prove BE between different strengths (3 mg, 7 mg , 14 mg vs 1.5 mg, 4 mg, 9 mg) of semaglutide tablets and EMA accepted it. As a generic company can we use the same approach for EMA?

Regards,
QA

1 https://link.springer.com/article/10.1007/s13300-024-01674-8

Complete thread:

UA Flag
Activity
 Admin contact
23,362 posts in 4,906 threads, 1,678 registered users;
123 visitors (0 registered, 123 guests [including 9 identified bots]).
Forum time: 13:23 CET (Europe/Vienna)

I have not failed 700 times. I have not failed once.
I have succeeded in proving
that those 700 ways will not work.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5